News & Updates

A territory-wide, retrospective cohort study in Hong Kong has shown that molnupiravir and nirmatrelvir/ritonavir are effective in reducing the risks of hospitalization and inpatient disease progression among older patients residing in nursing homes.

Critically ill patients with sepsis or septic shock who use ursodeoxycholic acid (UDCA) do not seem to experience improvement in shock severity and resolution, reveals a recent study. However, they have a higher chance of being extubated and not needing mechanical ventilation (MV) on the third day of admission to the intensive care unit (ICU).

A case-control surveillance study has found no link between monovalent COVID-19 boosters and miscarriage before 20 weeks of pregnancy.

Interim results from the ongoing Study 306, a phase III open-label trial, show improved immunogenicity and safety of the bivalent Omicron-containing mRNA-1273.214 vaccine in children 6 months to 5 years of age, both as a primary series and a booster.

New drug applications approved by US FDA as of 16-31 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.